Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This is a single arm open-label multi-center phase II study, investigating disease control
rate after 18 weeks of treatment with afatinib/cetuximab combination therapy in patients with
advanced non-small cell lung cancer (NSCLC) harboring an EGFR exon 20 insertion.
Phase:
Phase 2
Details
Lead Sponsor:
The Netherlands Cancer Institute
Collaborators:
Boehringer Ingelheim Merck Serono International SA